Akebia Therapeutics Inc. Common Stock (AKBA)

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric cit…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

194

Website

www.akebia.com

Fundamentals

1-day range

$0.9056$0.9327

Market cap

$351.42M

P/E (trailing)

—

P/E (forward)

-2.79

EPS (trailing)

$-0.12

Dividend yield

—

Beta

0.23

Avg. volume

5.37M

Forecasts

5 analyst ratings

Akebia Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AKBA

  Akebia Therapeutics Inc. Common Stock

  $0.879

  ▼ 6.49%
  Market cap $351.42MP/E —
  $0.814$3.22
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $351.32MP/E —
  $5.14$10.42
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $349.38MP/E —
  $5.85$33.68
• ZNTL

  Zentalis Pharmaceuticals Inc. Common Stock

  $3.8

  ▼ 2.06%
  Market cap $331.02MP/E —
  $1.21$6.95
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• VNDA

  Vanda Pharmaceuticals Inc. Common Stock

  $5.29

  ▼ 2.76%
  Market cap $314.51MP/E —
  $4.27$9.94

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

98.35M

Total value held

$132.78M

Institutional holders

167